CD274 and non-small cell lung carcinoma: The PACIFIC trial (Antonia et al., 2018) investigated the efficacy of definitive chemo-radiation followed by 1 year of consolidation with durvalumab (PD-L1 inhibitor) versus placebo on progression-free survival (PFS) and overall survival (OS) in patients with locally advanced, unresectable NSCLC.